SCHEMBL430813

SCHEMBL430813

Cc1ccc(P(c2ccc(C)cc2)c2cc(-c3c(P(c4ccc(C)cc4)c4ccc(C)cc4)ccc4ccccc34)c3ccccc3c2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 1/20 0.35
CYP1A2 P05177 3/20 0.33
ALDH1A1 P00352 3/20 0.33
CYP2A6 P11509 3/20 0.33
HSD17B10 Q99714 2/20 0.33
HPGD P15428 2/20 0.33
HIF1A Q16665 1/20 0.33
CYP1B1 Q16678 1/20 0.33
TDP1 Q9NUW8 1/20 0.32
HKDC1 Q2TB90 2/20 0.32
RRM1 P23921 1/20 0.32
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
KMT2A Q03164 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
MAPT P10636 2/20 0.31
FLT3 P36888 1/20 0.31
MAOA P21397 2/20 0.31
MAOB P27338 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23943725 0.92 CYP2A6 (0.38) GPR84CYP1A2ALDH1A1CYP2A6HSD17B10
SCHEMBL20956678 0.89 TDP1 (0.36) GPR84ALDH1A1CYP2A6HSD17B10HPGD
SCHEMBL2949327 0.86 DHFR (0.40) GPR84CYP1A2ALDH1A1CYP2A6TDP1
SCHEMBL29176 0.84 MAPT (0.39) CYP1A2ALDH1A1CYP2A6HSD17B10HPGD
SCHEMBL29361524 0.84 MAPT (0.39) CYP1A2ALDH1A1CYP2A6HSD17B10HPGD
Hydrochloric Acid SCHEMBL5566890 0.83 DHFR (0.38) GPR84CYP1A2ALDH1A1CYP2A6TDP1
SCHEMBL9116348 0.81 MAPT (0.37) GPR84CYP1A2ALDH1A1CYP2A6HSD17B10
Bromide SCHEMBL7948384 0.81 MAPT (0.37) CYP1A2ALDH1A1CYP2A6HSD17B10HPGD
Hydrochloric Acid SCHEMBL7937215 0.81 RAB9A (0.40) CYP1A2ALDH1A1CYP2A6HSD17B10HPGD
Bromide SCHEMBL7948386 0.81 MAPT (0.37) CYP1A2ALDH1A1CYP2A6HSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210323970-A1 METHOD FOR PRODUCING A SPIROOXINDOLE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2021-10-21 US disclosed
US-9376447-B2 Transfer hydrogenation of cyclopamine analogs INFINITY PHARMACEUTICALS, INC. (US) 2016-06-28 US disclosed
US-9376447-B2 Transfer hydrogenation of cyclopamine analogs INFINITY PHARMACEUTICALS, INC. (US) 2016-06-28 US disclosed
US-20120065400-A1 Transfer Hydrogenation of Cyclopamine Analogs INFINITY PHARMACEUTICALS, INC. (US) 2012-03-15 US disclosed
US-20120065400-A1 Transfer Hydrogenation of Cyclopamine Analogs INFINITY PHARMACEUTICALS, INC. (US) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065400-A1 Transfer Hydrogenation of Cyclopamine Analogs HVCN1, KCNQ4, KCNQ5 GPR84 2264/4885CYP1A2 317/4885ALDH1A1 1597/4885
US-20210323970-A1 METHOD FOR PRODUCING A SPIROOXINDOLE DERIVATIVE MDM2, TP53, RB1 GPR84 1250/4885CYP1A2 2604/4885ALDH1A1 628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.